Evidence map›Paper›PMID 26158517›Full record

ArticleCell death & disease2015

Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons.

J C Koch, F Bitow, J Haack, Z d'Hedouville, J-N Zhang, L Tönges, U Michel, L M A Oliveira, T M Jovin, J Liman and 3 more

Abstract read
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

J C KochDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany.
F BitowDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany.
J HaackDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany.
Z d'HedouvilleDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany.
J-N ZhangDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany.
L TöngesDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany.
U MichelDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany.
L M A OliveiraLab of Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.
T M Jovin1] Lab of Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany [2] Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany.
J Liman1] Department of Neurology, University Medicine Göttingen, Göttingen, Germany [2] Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany.
L TatenhorstDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany.
M Bähr1] Department of Neurology, University Medicine Göttingen, Göttingen, Germany [2] Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany.
P Lingor1] Department of Neurology, University Medicine Göttingen, Göttingen, Germany [2] Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany.ORCID 0000000193627096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many neuropathological and experimental studies suggest that the degeneration of dopaminergic terminals and axons precedes the demise of dopaminergic neurons in the substantia nigra, which finally results in the clinical symptoms of Parkinson disease (PD). The mechanisms underlying this early axonal degeneration are, however, still poorly understood. Here, we examined the effects of overexpression of human wildtype alpha-synuclein (αSyn-WT), a protein associated with PD, and its mutant variants αSyn-A30P and -A53T on neurite morphology and functional parameters in rat primary midbrain neurons (PMN). Moreover, axonal degeneration after overexpression of αSyn-WT and -A30P was analyzed by live imaging in the rat optic nerve in vivo. We found that overexpression of αSyn-WT and of its mutants A30P and A53T impaired neurite outgrowth of PMN and affected neurite branching assessed by Sholl analysis in a variant-dependent manner. Surprisingly, the number of primary neurites per neuron was increased in neurons transfected with αSyn. Axonal vesicle transport was examined by live imaging of PMN co-transfected with EGFP-labeled synaptophysin. Overexpression of all αSyn variants significantly decreased the number of motile vesicles and decelerated vesicle transport compared with control. Macroautophagic flux in PMN was enhanced by αSyn-WT and -A53T but not by αSyn-A30P. Correspondingly, colocalization of αSyn and the autophagy marker LC3 was reduced for αSyn-A30P compared with the other αSyn variants. The number of mitochondria colocalizing with LC3 as a marker for mitophagy did not differ among the groups. In the rat optic nerve, both αSyn-WT and -A30P accelerated kinetics of acute axonal degeneration following crush lesion as analyzed by in vivo live imaging. We conclude that αSyn overexpression impairs neurite outgrowth and augments axonal degeneration, whereas axonal vesicle transport and autophagy are severely altered.

Indexed as

alpha-SynucleinAmino Acid SubstitutionAnimalsAutophagyAxonsDopamineDopaminergic NeuronsGene Expression RegulationHumansNerve DegenerationNeuritesParkinson DiseaseRatsSubstantia Nigraalpha-SynucleinDopamine

Identifiers

PMID26158517
PMCPMC4650722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.